BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep 2017;7:4099. [PMID: 28642489 DOI: 10.1038/s41598-017-03910-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Bharat TA, Kukulski W. Cryo‐Correlative Light and Electron Microscopy. In: Verkade P, Collinson L, editors. Correlative Imaging. Wiley; 2019. pp. 137-53. [DOI: 10.1002/9781119086420.ch8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
2 Tharmalingam T, Han X, Wozniak A, Saward L. Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. Hum Vaccin Immunother 2021;:1-20. [PMID: 34010089 DOI: 10.1080/21645515.2021.1886560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Banadyga L, Wong G, Qiu X. Small Animal Models for Evaluating Filovirus Countermeasures. ACS Infect Dis 2018;4:673-85. [PMID: 29457711 DOI: 10.1021/acsinfecdis.7b00266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Dowall SD, Kempster S, Findlay-Wilson S, Mattiuzzo G, Graham VA, Page M, Hewson R, Almond N. Towards quantification of protective antibody responses by passive transfer of the 1st WHO International Standard for Ebola virus antibody in a guinea pig model. Vaccine 2020;38:345-9. [PMID: 31668821 DOI: 10.1016/j.vaccine.2019.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Sizikova TE, Lebedev VN, Borisevich SV. [Virus specific antibody - based remedies for the urgent prevention and treatment of Ebola virus disease]. Ter Arkh 2019;91:98-104. [PMID: 32598619 DOI: 10.26442/00403660.2019.11.000164] [Reference Citation Analysis]
6 Findlay-wilson S, Easterbrook L, Smith S, Pope N, Humphries G, Schuhmann H, Ngabo D, Rayner E, Otter AD, Coleman T, Hicks B, Graham VA, Halkerston R, Apostolakis K, Taylor S, Fotheringham S, Horton A, Tree JA, Wand M, Hewson R, Dowall SD. Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105332] [Reference Citation Analysis]
7 Müller H, Fehling SK, Dorna J, Urbanowicz RA, Oestereich L, Krebs Y, Kolesnikova L, Schauflinger M, Krähling V, Magassouba N, Fichet-Calvet E, Ball JK, Kaufmann A, Bauer S, Becker S, von Messling V, Strecker T. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. NPJ Vaccines 2020;5:71. [PMID: 32802410 DOI: 10.1038/s41541-020-00219-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Liu J, Zhang Z, Bai A, Sha Y, Ma L, Qin S, Chen F, Qin S, Wu J. Prophylactic Efficacy of Equine Immunoglobulin F(ab')2 Fragments Against Feline Parvovirus. Appl Biochem Biotechnol 2021. [PMID: 34086256 DOI: 10.1007/s12010-021-03591-z] [Reference Citation Analysis]